Artemisinin Resistance In Malaria Treated With IV Artesunate (ARIMTIA)
A Multicenter, Prospective, Observational Study to Assess the Efficacy of Artesunate in Malaria Treated With Parenteral Artesunate in Areas With Artemisinin Resistance A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)
The spread of artemisinin resistant falciparum malaria presents new challenges to both the control and treatment of malaria. Loss of ring stage susceptibility to the artemisinins might jeopardize the use of parenteral artesunate as the first line drug for the treatment of severe falciparum malaria.
The purpose of this study is to assess the effect of artemisinin resistance (defined by a Kelch13 mutation with known functional significance) in P. falciparum malaria requiring parenteral artesunate treatment on lactate clearance parameters.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The investigators propose a multi-center observational study to assess the effect of artemisinin resistance (as defined by the presence of relevant Kelch13 mutations) on the efficacy of parenteral artesunate for the treatment of malaria, stratified for disease severity on admission.
The patients will receive the standard intravenous treatment for severe malaria (parenteral artesunate). Primary endpoints will be the plasma lactate concentration at 12 hours as a proportion of the plasma lactate at the start of treatment. Secondary endpoints will be improvement of Glasgow or Blantyre Coma Scores and other indicators of neurological recovery or deterioration, parasite clearance rates, time until resolution of fever, development of new severity or neurological signs under treatment, development of severe anemia, renal and hepatic injury, total duration of hospitalization , outcome of pregnancy in pregnant female patients, mortality rates and the necessity to treat with antibiotics, need for renal replacement therapy, mechanical ventilation, blood transfusion and rescue treatments.
On admission blood will be taken for the determination of genetic markers of antimalarial resistance (including Kelch13 mutations of known functional significance) and in vitro sensitivity tests to artemisinins and other antimalarials. Additional blood samples will be used for measuring plasma organic acid biomarkers of severe falciparum malaria measured by mass spectrometry. Difference in the kinetics of these acids will be an additional endpoint. Difference in the transcriptome of p. falciparum will be assessed by RNA measurements at baseline and 3 timepoints during treatment.
The proposed sites in Vietnam and Cambodia have been chosen based on the prevalence of artemisinin resistant falciparum malaria, incidence of severe malaria and local experience in participating in clinical trials.
Interim analysis:
To ensure timely recognition of the effect of artemisinin resistance on the outcome in malaria treated with parenteral artesunate, an interim analysis will be performed after the inclusion of 60 patients or one malaria transmission season (whatever comes first). An independent Data Safety Board will assess whether the difference in outcome between infections with artemisinin resistant versus sensitive strains warrants early termination and reporting of the study.
Tipo de estudo
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Male or female, aged over 6 months old
Acute severe P. falciparum malaria or another indication to treat with IV artesunate. Defined as one or more of the following, occurring in the absence of an identified alternative cause, and in the presence of P. falciparum asexual parasitaemia:
- Prostration OR obtundation
- BCS<3 (preverbal children) or GCS<11 (adults)
- Convulsion in last 24 hours
- Suspected acidosis, manifesting as acidotic breathing
- Respiratory distress manifesting clinically (nasal flaring/indrawing) or oxygen saturation <92% or respiratory rate >30/min
- History of anuria
- Jaundice and/or hemoglobinuria
- Hemoglobin <7 g/dl or hematocrit <20%
- Significant bleeding including recurrent or prolonged bleeding from nose gums or venipuncture sites; hematemesis or melena
- Shock defined as systolic blood pressure <70 mm Hg (children) OR <80 mm Hg (adults)
- P. falciparum parasitaemia >10%
Indication for parenteral antimalarial treatment (as assessed by clinician) other than nausea and vomiting. These may include laboratory findings such as:
- Creatinine >2.5 mg/dL (>220uM/L) or blood urea >56mg/dL (>20 mM/L)
- Glucose <4.0 mmol/L (<72mg/dL)
- Bilirubin > 3 mg/dL (>50uM/L)
- Hemoglobin <7g/dL or Hematocrit <20%
- P. falciparum parasitaemia >4%
- Venous plasma lactate >5 mM, Base deficit of >8meq/L or bicarbonate <15mM
- Written informed consent or consent by locally accepted representative in the case of patients rendered incapable of providing consent due to illness
Exclusion Criteria:
- History of 2 or more doses of parenteral antimalarial treatment in the previous 24 hours
- History of allergy or known contraindication to artemisinins
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Study subjects
Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.
|
Intravenous Artesunate 2.4 mg/kg
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Absolute reduction of lactate
Prazo: 12 hours
|
Absolute reduction of lactate at 12 hours after the first artesunate treat-ment compared to baseline.
|
12 hours
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time needed until a plasma lactate concentration <2 mmol/L
Prazo: 42 days
|
42 days
|
|
|
Change in Glasgow Coma Score (GCS) or Blantyre Coma Score (BCS)
Prazo: 12 hours
|
at 12 hours after initial treatment and coma recovery time defined as GCS>10 or BCS>3 and GCS=15 and BCS=5
|
12 hours
|
|
Base excess clearance after 12 hours
Prazo: 42 days
|
Base excess clearance after 12 hours as proportion of the base excess at presentation
|
42 days
|
|
Time until a base excess concentration ≥ minus 2 mmol/L
Prazo: 42 days
|
42 days
|
|
|
Time to resuming the ability to sit, eat, drink, stand unsupported and walk
Prazo: 42 days
|
42 days
|
|
|
The parasite clearance half-life
Prazo: 48 hours
|
48 hours
|
|
|
The parasite clearance ratios at H28 and H48 compared to parasite count on admission
Prazo: 48 hours
|
48 hours
|
|
|
The parasite clearance time for parasite count to fall to 50%, 90% and 99% of initial parasite density
Prazo: 7 days
|
7 days
|
|
|
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at baseline
Prazo: H0
|
H0
|
|
|
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H6
Prazo: H6
|
H6
|
|
|
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H12
Prazo: H12
|
H12
|
|
|
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H48
Prazo: H48
|
H48
|
|
|
Time until resolution of fever
Prazo: 14 days
|
(time until tympanic temperature first <37.5 Celsius and below 37.5C for 24 h)
|
14 days
|
|
Proportion of patients developing new malaria
Prazo: 42 days
|
Proportion of patients developing new malaria severity signs as defined in the 2014 WHO severe malaria guidelines
|
42 days
|
|
Proportion of patients developing new neurological signs assessed by neurological examination during hospitalization
Prazo: 42 days
|
42 days
|
|
|
Prevalence of neurological sequelae assessed by neurological examination at discharge
Prazo: 42 days
|
42 days
|
|
|
Prevalence of neurological sequelae assessed by neurological examination at day 7
Prazo: 7 days
|
7 days
|
|
|
Prevalence of neurological sequelae assessed by neurologicalexamination at day 14
Prazo: 14 days
|
14 days
|
|
|
Prevalence of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal
Prazo: 28 days
|
28 days
|
|
|
Prevalence of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal
Prazo: 42 days
|
42 days
|
|
|
Severity of neurological sequelae assessed by neurological examination at discharge
Prazo: 42 days
|
42 days
|
|
|
Severity of neurological sequelae assessed by neurological examination at day 7
Prazo: 7 days
|
7 days
|
|
|
Severity of neurological sequelae assessed by neurological examination at day 14
Prazo: 14 days
|
14 days
|
|
|
Severity of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal
Prazo: 28 days
|
28 days
|
|
|
Severity of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal
Prazo: 42 days
|
42 days
|
|
|
Proportion treated with quinine
Prazo: 42 days
|
as a rescue treatment, antibiotics, blood products, anticonvulsants, renal replacement therapy, mechanical ventilation therapy, vasopressive drugs and oxygen therapy
|
42 days
|
|
In hospital mortality
Prazo: 42 days
|
42 days
|
|
|
Day 7, 14 hemoglobin or hematocrit levels
Prazo: 42 days
|
and in addition at day 28 and 42 if abnormal at day 14 or day 28 respectively
|
42 days
|
|
Creatinine levels daily
Prazo: 42 days
|
during the first four days and thereafter on day 7 and 14 and in addition on day 28 and 42 if abnormal on day 14 or day 28 respectively
|
42 days
|
|
Bilirubin, Alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase levels daily
Prazo: 42 days
|
during the first four days and thereafter on day 7, 14 and in addition on day 28 and 42 if abnormal on day 14 or 28 respectively
|
42 days
|
|
Plasma biomarkers of severe (artemisinin resistant) malaria
Prazo: 42 days
|
42 days
|
|
|
outcome of pregnancy during hospitalization
Prazo: 42 days
|
If pregnant
|
42 days
|
|
Time until discharge
Prazo: 42 days
|
42 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Prof. Arjen M Dondorp, MD, Mahidol Oxford Research Unit (MORU)
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- BAKMAL1504
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .